[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630835":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":20,"responsibleParty":34,"collaborators":20,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":20,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":20,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":20},{"fullName":5,"class":6},"Hospital do Coracao","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm","EXPERIMENTAL","Hypofractonated Radiotherapy",[13],"Radiation: Hypofractionated Radiation Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Hypofractionated Radiation Therapy","60 Gy in 20 fractions of 3 Gy",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Douglas G Castro, MD PhD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Alexandre B Cavalcanti, MD PhD","CONTACT","55 11 3053 6611","abiasi@hcor.com.br",{"name":32,"role":28,"phone":29,"phoneExt":20,"email":33},"Karina L Negrelli, VMD","knegrelli@hcor.com.br",{"type":35,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100630835","hypofractionated-radiotherapy-plus-temozolamide-in-patients-younger-than-70-years-with-glioblastoma-100630835",false,"NCT07492836","Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma","Prospective, Pilot Study to Evaluate Hypofractionated Radiotherapy Associated With Temozolomide in Patients Aged 18 to 70 Years With Glioblastoma (HypoGBM)","HipoGBM","Inclusion Criteria:\n\n* Initial histological diagnosis of glioblastoma\n* Age \\> 18 and \\\u003C 70 years;\n* Karnofsky Performance Status \\> 70%;\n* Patient consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients submitted to any type of previous radiotherapy in the cranial region;\n* Multicentric tumors;\n* Contraindication to chemotherapy with temozolomide;\n* Contraindications for performing magnetic resonance imaging (MRI), such as the use of implants or metallic prostheses;\n* Pregnant women or women of childbearing age who refuse to undergo the beta-HCG test before treatment and contraception during the intervention.","ALL","18 Years","70 Years",{"count":48,"type":49},10,"ESTIMATED","INTERVENTIONAL",[52],"NA","The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a brain tumor known as glioblastoma.",[55],"Glioblastoma (GBM)",[57,58],"Radiotherapy","Temozolamide","NOT_YET_RECRUITING","2026-03-19",{"date":62,"type":63},"2026-03-25","ACTUAL",{"date":65,"type":49},"2026-04",{"date":67,"type":49},"2029-04",{"name":5,"class":6}]